Company Overview
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty pharmaceutical distribution, and clinical programs for whole-person health outcomes. The Cigna Healthcare segment comprises U.S. Healthcare and International Health, delivering comprehensive medical and coordinated solutions such as employer medical plans, individual and family plans, behavioral health, consumer health engagement, dental, pharmacy management, stop-loss insurance, global health care, and local health care solutions, as well as health care benefits for mobile individuals and employees of multinational organizations. The company offers other operations, including corporate-owned life insurance, reinsurance, and certain run-off and non-strategic businesses. The company distributes its products and services through brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Why Investors Should Care
Generates a return on equity of 16.3%, reflecting efficient use of shareholder capital.
Net profit has compounded at 13.8% per year over the last five years.
Revenue has grown at a 23.9% CAGR over the past five years.
Trades at a P/E of 12.1, below the sector median of 25.4.
Offers a dividend yield of 2.09%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $274.90B (+11.2% YoY); net profit $5.96B.
- Trailing 12 Months Year-on-year growth — revenue +4.6%, earnings +29.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 23.9%, profit CAGR 13.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 23.94% |
| 1 Year: | 4.60% |
Compounded Profit Growth
| 5 Years: | 13.76% |
| 1 Year: | 29.10% |
Stock Price Performance
| 1 Year: | +2.31% |
| 6 Months: | +9.98% |
| 3 Months: | +10.90% |
| 1 Month: | +2.89% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.97 · Neutral
P/E of 12.13 is below the sector median of 25.41 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 23.9% over 5 years.
- Profit CAGR of 13.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CI The Cigna Group SPX | 303.35 | 12.13 | $80.25B | 2.09% | 9.06% | 16.27% | 23.94% | 13.76% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.43B | 10.37B | 10.37B | 10.63B | 11.41B | 11.48B | 11.46B | 14.30B | 37.95B | 38.82B | 38.56B | 38.24B | 38.47B | 39.27B | 40.95B | 40.97B | 43.13B | 44.29B | 44.01B | 45.48B | 45.28B | 46.52B | 48.59B | 49.05B | 57.26B | 60.52B | 63.69B | 65.50B | 67.18B | 69.75B | 68.49B |
| Operating Income | - | - | - | - | 1.31B | 1.16B | 1.13B | - | 2.23B | 2.16B | 2.12B | - | 2.06B | 2.64B | 2.11B | 1.96B | 2.15B | 2.29B | 2.19B | 2.37B | 2.14B | 2.02B | 2.22B | 2.24B | 2.26B | 2.41B | 2.58B | 1.97B | 2.31B | 2.58B | 2.36B |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.32B | - | - | 1.65B |
| Diluted EPS | 2.30 | 3.15 | 2.21 | 1.07 | 3.72 | 3.29 | 3.14 | 0.55 | 3.56 | 3.70 | 3.57 | 2.60 | 3.15 | 4.73 | 3.78 | 3.30 | 4.25 | 4.80 | 3.73 | 4.89 | 8.97 | 4.24 | 4.92 | 4.74 | -0.97 | 5.45 | 2.63 | 4.85 | 5.71 | 6.98 | 6.26 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 39.84B | 41.81B | 48.65B | 153.57B | 160.40B | 174.07B | 180.52B | 195.26B | 247.12B | 274.90B |
| Operating Income | 3.09B | 3.94B | 4.16B | 8.08B | 8.15B | 7.94B | 8.45B | 8.54B | 9.42B | 9.20B |
| Net Income | 1.87B | 2.24B | 2.64B | 5.10B | 8.46B | 5.37B | 6.70B | 5.16B | 3.43B | 5.96B |
| Diluted EPS | 7.19 | 8.77 | 10.54 | 13.44 | 22.96 | 15.75 | 21.41 | 17.39 | 12.12 | 22.18 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 61.76B | 153.23B | 155.77B | 155.45B | 154.89B | 143.88B | 152.76B | 155.88B | 157.92B |
| Total Equity | 12.02B | 13.70B | 13.71B | 41.03B | 45.34B | 50.32B | 47.11B | 44.67B | 46.22B | 41.03B | 41.71B |
| Cash & Equivalents | 1.97B | 3.19B | 2.97B | 3.85B | 4.62B | 10.18B | 5.08B | 5.92B | 7.82B | 7.55B | 7.68B |
| Total Liabilities | - | - | 48.00B | 112.15B | 110.39B | 105.06B | 107.70B | 99.13B | 106.41B | 114.64B | 116.05B |
| Current Liabilities | - | - | 11.01B | 31.89B | 40.14B | 36.02B | 43.57B | 41.23B | 48.72B | 57.98B | 56.34B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 4.03B | 4.09B | 3.77B | 9.48B | 10.35B | 7.19B | 8.66B | 11.81B | 10.36B | 9.60B |
| Investing Cash Flow | -2.57B | -1.70B | -26.38B | -734.00M | 2.98B | -3.61B | 3.10B | -5.17B | -2.10B | -4.41B |
| Financing Cash Flow | -225.00M | -2.65B | 23.52B | -7.19B | -8.53B | -8.21B | -11.24B | -4.29B | -7.65B | -6.42B |
| Capital Expenditure | -461.00M | -471.00M | -528.00M | -1.05B | - | - | - | - | - | - |
| Free Cash Flow | 3.56B | 3.62B | 3.24B | 8.44B | - | - | - | - | - | - |
| Share Buybacks | 139.00M | 2.73B | 342.00M | 1.99B | 4.04B | 7.74B | 7.61B | 2.28B | 7.03B | 3.62B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 7.8% | 9.4% | 8.6% | 5.3% | 5.1% | 4.6% | 4.7% | 4.4% | 3.8% | 3.3% |
| Net Margin % | 4.7% | 5.4% | 5.4% | 3.3% | 5.3% | 3.1% | 3.7% | 2.6% | 1.4% | 2.2% |
| ROE % | 13.6% | 16.3% | 6.4% | 11.3% | 16.8% | 11.4% | 15.0% | 11.2% | 8.4% | 14.3% |
| ROCE % | - | 7.8% | 3.4% | 7.0% | 6.8% | 7.1% | 8.2% | 8.2% | 9.6% | 9.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.54% | 22.60M | $6.31B |
| 2 | Vanguard Capital Management LLC | 6.47% | 17.12M | $4.78B |
| 3 | State Street Corporation | 4.64% | 12.28M | $3.43B |
| 4 | Massachusetts Financial Services Co. | 4.38% | 11.60M | $3.24B |
| 5 | Dodge & Cox Inc. | 4.37% | 11.56M | $3.23B |
| 6 | FMR, LLC | 4.14% | 10.96M | $3.06B |
| 7 | Sanders Capital, LLC | 3.89% | 10.29M | $2.87B |
| 8 | Geode Capital Management, LLC | 2.34% | 6.20M | $1.73B |
| 9 | Vanguard Portfolio Management LLC | 2.33% | 6.16M | $1.72B |
| 10 | GQG Partners LLC | 2.27% | 6.00M | $1.68B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CI
Why Cigna (CI) Stock Is Up Today - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOVlZpaHBFQzJoYW5yWjdCejI2bHpWS1liUnFFUlc4U0NaMEhILUZ1WU9aZFd3U3owZnlaeEVpVUFqSGM0NWxNOTFCbjB3Rnh1LUlxQTlEUlI2QW02dGRkWm1YMmJfOWlhQlY3SHZqeXBpWkY1V2s4ckRSYWVDazBBYkFLYURCTUVGN1dBdU…
Why The Cigna Group (CI) Stock Is Up Today - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxQSUZObTZXMjZhVk5LX2kxeGlDT3MzYVduNk9xLUtyUUdidnpNbzAtWEFmY2Rsemc2Y1psOFg4c1F3eUdiOTFqUGhlSHZBU2ZBUzhlbGl2ajAzN001ZTUtYkRaMExzSmk5b0ZtcEhGYTNnaHA1TkNmbjJvSGhoRjVvbjdhSUE5dw?oc=5" t…
Cigna Corp (CI) Stock Price Today: $289.67 - Pluang
<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTE1vWV9KV0JqZWN3UjBUT2dyZ1dvY3IyT0NYZllDVXZYMDRvVjRJeDcxTWp4QzBvZjREeFdNeHFoLWZwNVVjQWk0THNIel93bG1CbkNRbXEtcw?oc=5" target="_blank">Cigna Corp (CI) Stock Price Today: $289.67</a>&nb…
Stocks making big moves yesterday: RXO, Progyny, Cigna, GoodRx, and Domino's - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxQWWlQRVA4MUpucnpyOVpzYUpfV2NCemo5bVN3elI1YWhBQnV3d25nVmRPRTV2RjFVdndYem5talpYb1J0Y3AwYlliWm5PandKVWhJSl9VNV84UXZzWURHUkpkRExvVmJRaTVyQkZjYWdnMzVCd21abl9qbnlrVFptUFNWNUphU3ozZXJCcC…
ADGO.CI Stock Price and Chart — BCBA:ADGO.CI - TradingView
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE84WmRUUzN6WmpQRm1hSFMzbVhCbUc0TDJVdGhyNHpmcVBEZzZHU0hTVU9ZVjlyU2tQR3pHaUVVY3duQmdVNWc3UEV4MWQ3M1R6MFJGdnRvMWVJbkljVGc?oc=5" target="_blank">ADGO.CI Stock Price and Chart — BCBA:ADG…
Cigna Group (CI) Turns To AI Pharmacy Care On A Narrative That Still Looks Undervalued - simplywall.st
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxOcTVvQS10aXVPdWdBbDc5OXdFOVdGMnBlTFB2NFVXMllXblc3U1ozWWY2RExOMTlFbWc5NWp5VUpDQTlEUUdCcDFpckU2dDRJVlk4ZC1iaUFMWUZTbUt4YjB3OWNJMjBJUFhXMXNKM29Tal83VUtNS2RIU0tXVmtIQ2hxTExJOWxhWkk5c2…
CI — Frequently Asked Questions
What is the current share price of The Cigna Group (CI)?
As of 2026-07-14 21:23 PDT, The Cigna Group (CI) trades at $303.35 on NYSE. Its 52-week range is $240.32 to $305.80.
What is the market capitalisation of CI?
The Cigna Group (CI) has a market capitalisation of $80.25B on NYSE.
What is the P/E ratio of CI?
CI trades at a trailing price-to-earnings (P/E) ratio of 12.13. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.87.
Does CI pay a dividend?
The Cigna Group (CI) currently offers a dividend yield of 2.09%.
What is the return on equity (ROE) of CI?
CI has a return on equity (ROE) of 16.27%. Its return on capital employed (ROCE) is 9.06%.
Is CI a good stock to buy?
This page provides a data-driven analysis of The Cigna Group (CI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.